<DOC>
	<DOCNO>NCT00360932</DOCNO>
	<brief_summary>5 year , open-label study evaluate safety SCULPTRA sign lipoatrophy face least 100 evaluable subject human immunodeficiency virus .</brief_summary>
	<brief_title>Facial Lipoatrophy Correction Experience With SCULPTRA ( `` FACES '' Study )</brief_title>
	<detailed_description />
	<mesh_term>Facies</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects seropositive human immunodeficiency virus ; In investigator 's judgment , high probability 5 year survival compliance study visit schedule ; Initiating SCULPTRA treatment ; Ability comprehend sign inform consent document prior study enrollment . No waiver , prospective retrospective , deviate way inclusion/exclusion criterion clinical study subject , define study protocol , grant clinical investigator . EXCLUSION CRITERIA Any active skin inflammation infection near treatment area ; Any hypersensitivity component SCULPTRA Previous treatment SCULPTRA product facial lipoatrophy ; Pregnancy breastfeed anticipate become pregnant study period ; Any exclude factor , accord investigator 's judgment , would preclude enrollment study . No waiver , prospective retrospective , deviate way inclusion/exclusion criterion clinical study subject , define study protocol , grant clinical investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>facial lipoatrophy</keyword>
	<keyword>HIV/AIDs</keyword>
</DOC>